LIFT BioSciences
Generated by Meeveem AI
"Pioneering neutrophil cell therapies to kill solid tumours and restore immune response"
About LIFT BioSciences
LIfT BioSciences, renamed Lift Therapeutics in 2026, develops Immunomodulatory Alpha Neutrophil (IMAN) cell therapies for hard-to-treat solid cancers. Its allogeneic platform uses donor-derived neutrophils, designed to infiltrate tumours, kill cancer cells and activate broader immune responses without relying on a specific tumour antigen.
Founded in 2016 and based in London, the company also has offices in Galway and Boston. It is developing unmodified and engineered IMAN programmes alongside a scalable manufacturing platform. A planned first-in-human Phase 1 study will assess safety, biodistribution and anti-tumour activity in advanced cervical and head and neck cancers; the company’s September 2026 update targets early 2027.
From biology to clinical manufacture
The team includes biology, translational biology, analytical sciences and process development functions. Its work links discovery and preclinical research with trial endpoints, analytical strategy, product characterisation and manufacturing scale-up as the IMAN platform progresses towards clinical manufacture.
25
Team Members
2016
Founded
Biotechnology
Sector
On-Site
Work Environment